WO2006071085A1

WO2006071085A1 - Tablet milk composition having immuno-modulating activity and preparation method thereof

Info

Publication number: WO2006071085A1
Application number: PCT/KR2005/004624
Authority: WO
Inventors: Joo-Whan Park; Sang-Dong Lim; Jeong-Ryong Do; Kee-Sung Kim
Original assignee: Korea Food Research Institute
Priority date: 2004-12-29
Filing date: 2005-12-29
Publication date: 2006-07-06
Also published as: KR20060061281A; KR20060088129A; WO2006137634A1; KR100649691B1; KR20060061280A; KR100651703B1; WO2006137635A1; KR100649692B1; KR20060061279A; KR100649690B1; WO2006137636A1

Abstract

The present invention relates to a tablet functional milk composition having immuno-modulating activity, comprising Acanthopanax senticosus extract, Radix Adenophorae extract, Agaricus bisporus extract and Pleurotus ostreatus extract, and a preparation method thereof.

Description

TABLET MILK COMPOSITION HAVING IMMUNO-MODULATING

ACTIVITY AND PREPARATION METHOD THEREOF

TECHNICAL FIELD

The present invention relates to a tablet type functional milk composition, comprising natural materials having excellent sensory characteristics and palatability, and having immuno-modulating activity, and to a preparation method thereof.

BACKGROUND ART

As the standard of living has been improved, an interest for health and longevity has been increased. However, adult diseases such as cancer by the decrease of immunity due to fatigue, stress, false eating habit, etc. have been raised as a new social problem.

In accordance with the western style eating habits, various western foods have gradually been increased in the country, and in particular, consumption of the dairy product such as milk, cheese and yogurt have gradually been increased according to the trend focusing on the health and the growth of children.

Domestic dairy industries have also been extended according to the increase of the dairy product consumption; however, the import of cheap dairy products from foreign countries has also been increased according to the trade liberalization, resulting in the loss of international competitiveness of the domestic dairy products, and thus, the total stock of powered milk is being increased. Under these circumstances, there is a need to develop functional dairy products containing the powered milk as a main ingredient and to increase the domestic milk consumption, so as to protect the dairy farmers and the milk processing companies.

Until now, the main current in dairy product was liquid products such as milk, processed milk or the like, or solid products such as cheese; however, such products are unsuitable to be easily taken because they require keeping and circulating in cold storage. Recently, the preference on the convenient food that the consumer can easily and conveniently eat has increased, and the necessity for the various kinds of foods such as substitute food for long-term travelers or mountain climbers, or such as an armament daily food, nutrition supplementary food or snacks for examinees or people who skip breakfast has also been raised.

Further, according to the current consumer trend that prefers natural foods having functionality and palatability, products having improved functionality and palatability aiming at various consumers are required. Accordingly, the necessity for providing tablet milk which is appropriate for adults as well as children has been gradually increasing. However, the tablet milk using natural material which can improve the immune activity of cell has not been studied or introduced yet. DETAILED DESCRIPTION OF THE INVENTION

TECHNICAL PROBLEM TO BE SOLVED

An object of the present invention is to provide a tablet type functional milk composition comprising natural materials having excellent sensory characteristics and good palatability, which has immuno-modulating activity and can be stored in an ambient temperature due to the excellent storage characteristics, and a preparation method thereof.

TECHNICAL SOLUTION

According to the invention, the above-mentioned object of the present invention is achieved by providing a tablet type functional milk composition that extracts of Acanthopanax senticosus, Radix Adenophorae, Agaricus bisporus and Pleurotus ostreatus capable of enhancing immuno-activity of cells are added to skim milk powder, and a preparation method thereof.

Accordingly, the tablet milk composition according to the present invention is characterized by comprising extracts of Acanthopanax senticosus, Radix Adenophorae, Agaricus bisporus and Pleurotus ostreatus as ingredients which enhance immune activity of cells.

The tablet milk composition according to the present invention may comprise powders of Agaricus bisporus and Pleurotus ostreatus instead of extracts thereof.

In addition to the above-mentioned ingredients enhancing the immune activity, the tablet milk composition according to the present invention may further comprise at least one other natural ingredients selected from the group consisting of colostrum powder, Ganoderma lucodum extract powder, Phellinus linteυs extract powder, ginseng powder, lactoferrin, glutamine peptide, lactose, crystalline oligosaccharide and combinations thereof.

The colostrum powder contains about 20% of immunoglobulin which is an immune ingredient, which has functions of defending from harmful substances and protecting the body from bacteria or viruses infection.

Ganoderma lucodum has been known to enhance immune ability of the body, thereby exhibiting remarkable effects for preventing adult diseases and recovering for fatigue.

Polysaccharide such as meshima of Phellinus linteus has been used for anti-cancer, immune therapy, etc. A hydrothermal extract of Phellinus linteus has been reported as having cancer inhibiting effect of digestive organs and as agonizing immune activity when it is used in combination with chemotherapy after the operation of a patient of cancer and the like.

Ginseng has been known to have several effects, which is enough to be called as a panacea. The most representative effects of Ginseng are vigorous operation, anti-stress and anti-fatigue effect, hangover effect, recovery for anemia, hematosis effect and radiation hazard protecting effect, hypertension prevention and curative effect, anticancer effect and immune function effect, diabetes curative effect, aphrodisiac operation, prevention of the aging, etc.

Lactoferrin is a strong antivirus and antibiotic substance that is only contained in colostrums of a cow and a human in the natural condition. It is a protein combined with iron, and it has an important function of combining and separating iron. Specifically, it combines with iron absorbed so as to prevent supply of iron required for the bacteria propagation, thereby inhibiting bacteria propagation, and the absorbed iron acts as a catalyst in supplying oxygen to all the cells in the body. Further, it has been known to prevent disease infection, malignant tumor, AIDS, cancer, etc.

Glutamine peptide is a hydrolysate of a wheat protein, and has been known for enhancing epithelial cell in the intestinal tract which is an initial defense system of the body functioning primary protection against the virus invasion, thereby exhibiting immune effect. Lactose is a disaccharide consisting of glucose and galactose, the sweet taste of which is one-fifth of sugar, and it functions as a binding agent during the tablet preparation.

Oligosaccharide arrives at the colon without decomposition by the digestive enzymes within the intestines, so as to be used by useful bacteria within the intestines including bifidus bacteria which inhabits in the colon, and controls the proliferation of harmful or pathogenic bacteria.

As shown in Table 1 , Acanthopanax senticosus extract powder is verified to improve immune activity. In the present invention, Acanthopanax senticosus extract may be in any form which is extracted by a hot water or an organic solvent, as long as it is allowed to be added to the food.

Preferably, Acanthopanax senticosus extract is obtained by the following method. Acanthopanax senticosus stem is sliced, and 5 to 10 times of water is added thereto, and the resultant is heated at 90 to 100⁰C perferably for 2 or more hours, and more preferably, for 2 to 3 hours, so as to extract. The obtained extract is filtered using a filter paper, and Acanthopanax senticosus extract and dextrin are homogeneously mixed in the ratio of 60:40% by weight of solid at 6O⁰C in a blending tank, and then the resultant mixture is dried by spraying at inlet temperature of 200 to 230⁰C and outlet temperature of 110 to 130⁰C. Acanthopanax senticosus extract powder is preferably added to a tablet milk composition in an amount of 3 to 7% by weight of the total weight of the tablet milk composition; however, it is not limited thereto. Radix Adenophorae has been known as being good for a person who easily feels fatigue because it aids the liver activity, and to promote digestive function by strengthening the stomach. For a long time, Radix Adenophorae has been known as a food which is famous for a tonic food, as well as a digestive, and strengthens the lungs, the spleen and the kidney. In the present invention, Radix Adenophorae extract powder having such functions is added to the tablet milk composition, so as to provide a function as an energy booster, in addition to a function of enhancing the immune activity. Radix Adenophorae extract powder may be added 1 to 3% by weight, but, it is not limited thereto.

However, if the amount of the extract powders of Acanthopanax senticosus and Radix Adenophorae to be added to the tablet milk composition is excessively large, the palatability of the tablet milk get may be getting worse due to the strong taste and flavor of such ingredients, while the functions such as immune activity, etc. can be greatly improved. On the contrary, if these ingredients are added in excessively small amount, the desired function may not be achieved. The content ranges of the extract powders of Acanthopanax senticosus and Radix Adenophorae as defined above conform to the preferable ranges which can satisfy both functionality and palatability.

Agaricus bisporus has been known to have distinguished anti-cancer activity and antibacterial effect, and in particular, performs anti-thrombus activity because it contains lentinasin. Pleurotus ostreatus* is the first harvested mushrooms by selecting and breeding a species having good taste among more than twenty kinds of Pleurotus ostreatus, followed by being cultivated in a cottonwood sawdust in which nutritive material is added. It has been known to be good for a diet. That is, Pleurotus ostreatus* is an improved mushroom which belongs to Pleurotus ostreatus. The tablet milk according to the present invention, the immune activity of which is enhanced, comprises Agaricus bisporus extract powder (or Agaricus bisporus powder) and Pleurotus ostreatus^* extract powder (or Pleurotus ostreatus* powder) in an amount of 1 to 3% by weight of the total weight of the tablet milk compositions, respectively.

In the present invention, the ingredient enhancing the immune activity is selected by the following method.

1. Selection of Immune Active Material

Table 1 below shows nitric oxide secretions of macrophages cell lines caused by the natural materials tested. As shown in Table 1 , Acanthopanax senticosus hydrothermal extract exhibits the most nitric oxide secretion as 91.93 μM among sixteen kinds of the natural materials.

Table 1

Notes) When the adding concentration is 0, nitric oxide secretion is 1.970 μM; dosage (100 μg/assay); the number of added cell: 2 x 10⁵ cells; O. D were measured at 540nm. Table 2 below shows interleukin-1α secretion of the macrophages cell lines caused by the natural material tested. As shown in Table 2, Agaricus bisporus hydrothermal extract exhibits the most interleukin-1α secretion as 203.13 pg/ml among sixteen kinds of the natural materials.

Table 2

Notes) N.D: Not Detected; dosage (100 μg/assay); the number of added cell: 2 x 10⁵ cells; O. D were measured at 450nm; when the adding concentration is 0, IL-1α is undetected.

Table 3 below shows the test results of the immune activity for the selected natural material extracts depending on the added concentrations thereof. As shown in Table 3, when 1000 μg/ml of hydrothermal extract was

added, the immune activity is the highest. Table 3

Notes) N.D: Not Detected; when the adding concentration is 0, IL-1α is undetected; nitric oxide: 12.58 μM/2 x 10⁵ cells; TNF: 32.42pg/ml

2. Pretreatment of the Immune Active Materials The stem of Acanthopanax senticosus is sliced, and water is added thereto at the ratio of 1 :5 by weight, and the resultant is heated and extracted at 100⁰C for 2 hours, and the liquid obtained is filtered through a filter paper to obtain Acanthopanax senticosus extract. The Acanthopanax senticosus extract is mixed with dextrin at the ratio of 60:40% by weight of the solid at 6O⁰C in a blending tank, and the resulting mixture is dried using a spray drier at inlet temperature of 200 to 230°C, and outlet temperature of 110 to130°C.

Radix Adenophorae, Ganoderma lucodum, Phellinus linteus, Agaricus bisporus and Pleurotus ostreatus* are sliced, respectively, and extracted in the same method as those of Acanthopanax senticosus. The respective extracts obtained are mixed with dextrin so as to prepare extract powders.

Further, in case that Agaricυs bisporus and Pleurotus ostreatus* are added, each of them is sliced and then dried at 50 to 60⁰C for 24 hours using a drier. The resultants are powdered in a pulverizer. Pleurotus ostreatus* is additionally ground for 12 hours using a ball mill so as to be powdered.

3. Content of the Ingredients

The tablet milk composition according to the present invention comprises 50 to 70% by weight of skim milk powder, 3.0 to 7.0% by weight of Acanthopanax senticosus extract powder, 1.0 to 3.0% by weight of Radix Adenophorae extract powder, 1.0 to 3.0% by weight of Agaricus bisporus extract powder (or Agaricus bisporus powder), and 1.0 to 3.0% by weight of Pleurotus ostreatus* extract powder (or Pleurotus ostreatus^* powder) based on the total weight of said milk composition.

When at least one ingredients selected from colostrum powder, Ganoderma lucodum extracts powder, Phellinus linteus extracts powder, ginseng powder, lactoferrin, glutamine peptide, lactose, crystalline oligosaccharide and combinations thereof are added as additional ingredients, the content may be 0 to 10% by weight of colostrum powder, 0.5 to 2.0% by weight of Ganoderma lucodum extract powder, 0.5 to 2.0% by weight of Phellinus linteus extract powder, 3.0 to 7.0% by weight of ginseng powder, 0.2 to 1.0% by weight of lactoferrin, 5.0 to 15.0% by weight of glutamine peptide, 1.0 to 5.0% by weight of lactose, and 1.0 to 3.0% by weight of crystalline oligosaccharide.

4. Blending In preparing the tablet milk composition according to the present invention, sub-materials such as colostrum powder, Acanthopanax senticosus extract powder, Radix Adenophorae extract powder, Agahcus bisporus extract powder (or Agaricus bisporus powder), Pleurotus ostreatus* extract powder (or Pleurotus ostreatus* powder), Ganoderma lucodum extract powder, Phellinus linteus extract powder, ginseng powder, lactoferrin, glutamine peptide, lactose, crystalline oligosaccharide and the like are mixed first, and then, skim milk powder is added thereto and mixed.

5. Aging The materials blended as above are aged at 5 to 25°C for 15 hours, so as to make the water balance of the materials achieved.

6. Tablet Preparation

Said mixed materials are prepared into of 0.15 to 2g of tablets using a tablet preparation device.

7. Coating

The tablet prepared as above is coated by spraying 3% hydroxypropylmethylcellulose (HPMC) solution in a mixed solvent of purified water and spirits in the ratio of 1.5:8.5 by volume.

Such coating is to prevent the ingredients in the tablet from direct contact with air, thereby improving the storage characteristics of the tablet. Therefore, the tablet functional milk composition according to the present invention can be stored in an ambient temperature.

8. Packing

A certain quantity of tablet is packed within a packing container having low water permeability, for example, a container made of PVDC.

EFFECT OF THE INVENTION

According to the present invention, a tablet type functional milk composition comprising natural materials, which have good palatability due to its excellent sensory characteristics, can enhance immune activity, and can be stored in an ambient temperature due to the excellent storage characteristics and a preparation method thereof are provided.

As shown in Tables 4 and 5, the tablet milk composition according to the present invention is verified to have a good palatability by the excellent sensory characteristics and enhance the immune activity of the cell.

Further, the surface of the tablet functional milk composition of the present invention is coated with HPMC, and thus, its storage characteristics are excellent. Therefore, it can be stored in an ambient temperature.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a flow chart for preparing a tablet milk composition having immune activity enhancing capability according to the present invention.

Figure 2 shows a procedure for measuring interleukin-1α secretion by macrophage cell lines with ELISA.

MODES FOR CARRYING OUT THE PREFERRED EMBODIMENTS

Hereinafter, the present invention will be explained in more detail with reference to examples and tests. However, such examples are merely provided to illustrate the present invention, not to limit the scope of the present invention thereto.

Example 1

Based on the total weight of the finally obtained tablet milk composition, 5.0% by weight of colostrum powder, 3.0% by weight of Acanthopanax senticosus extract powder, 1.5% by weight of Radix Adenophorae extract powder, 1.5% by weight of Agaricus bisporus extract powder, 1.5% by weight of Pleurotus ostreatus* extract powder, 1.0% by weight of Ganoderma lucodum extract powder, 1.0% by weight of Phellinus linteus extract powder, 5.0% by weight of ginseng powder, 0.5% by weight of lactoferrin, 10.0% by weight of glutamine peptide, 3.0% by weight of lactose and 2.0% by weight of crystalline oligosaccharide were mixed at 15⁰C for 30 minutes with a Hobart mixer. After 65% of skim milk powder was added to the resulting mixture, all materials were homogeneously mixed. The mixture was aged at 10⁰C for 3 hours, and was prepared into tablets using a tableting machine. The obtained tablets were coated with 3% of HPMC liquid, to obtain the tablet milk product according to the present invention.

Example 2

The tablet milk product was prepared in the same manner as described in Example 1 , except for using 63% by weight of skim milk powder, 5.0% by weight of colostrum powder, 5.0% by weight of Acanthopanax senticosus extract powder, 1.5% by weight of Radix Adenophorae extract powder, 1.5% by weight of Agaricus bisporus extract powder, 1.5% by weight of Pleurotus ostreatus* extract powder, 1.0% by weight of Ganoderma lucodum extract powder, 1.0% by weight of Phellinus linteus extract powder, 5.0% by weight of ginseng powder, 0.5% by weight of lactoferrin, 10.0% by weight of glutamine peptide, 3.0% by weight of lactose and 2.0% by weight of crystalline oligosaccharide.

Example 3

The tablet milk product was prepared in the same manner as described in Example 1 , except for using 61% by weight of skim milk powder, 5.0% by weight of colostrum powder, 7.0% by weight of Acanthopanax senticosus extract powder, 1.5% by weight of Radix Adenophorae extract powder, 1.5% by weight of Agaricus bisporus extract powder, 1.5% by weight of Pleurotus ostreatυs* extract powder, 1.0% by weight of Ganoderma lυcodum extract powder, 1.0% by weight of Phellinus linteus extract powder, 5.0% by weight of ginseng powder, 0.5% by weight of lactoferrin, 10.0% by weight of glutamine peptide, 3.0% by weight of lactose and 2.0% by weight of crystalline oligosaccharide.

Example 4

Test Example 1 : Sensory Evaluation Test 13 people who have been worked more than 2 years in the field of milk were selected as sensory evaluation test staffs, and the sensory evaluation test of color, taste, texture, overall palatability, etc. of the tablet milk manufactured by said examples 1 to 4 were carried out using 9 point evaluation method. The result is shown in below Table 4.

Table 4

Notes) 1 : Very poor; 5: Sensory evaluation limit; 9: Very good

Test Example 2: Immune Activity Test

According to the procedures described below, in vitro immune activities (secretions of nitric oxide, lnterleukin-1α (IL-1α) and tumor necrosis factor (TNF)) of the tablet milk products prepared in Examples 1 to 4 were tested.

(I) CeII Cultivation

As a culture medium for cultivating cells, Dulbecco's modified Eagle's medium, with or without phenol red, Gibco (DMEM), was used. A cultivation flask, a pipette, a microplate (96-well), etc. were all sterilized products, and the apparatus including a cultivation bottle, etc. were used after being sterilized at 121⁰C under the pressure of 15 Ib for 15 minutes in an autoclave. The culture medium was dissolved in tertiary purified water, and then sterilized by filtering through a sterilized filter (0.22μm pore size), followed by adding 10% fetal bovine serum and 1% streptomycin-penicilline. The temperature during cell washing and succeeding cultivation was maintained at 37⁰C.

When the cells were grown confluent on the bottom of the cultivation flask, the attached cells were separated and used. The cells were cultivated in CO₂ incubator maintaining the condition of 37⁰C, 5% CO₂, respectively, in a cultivation flask containing the DMEM. In the case of anchorage-dependent cells, the culture medium was removed and the cell was then treated with trypsin-EDTA (0.05% trypsin, 0.53mM EDTA-4Na) at 37°C for 5 minutes. These cells were separated, and then centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the culture medium was then centrifuged again. This procedure was repeated three times. The obtained cells were dispersed to a culture medium and then used by adjusting at a certain number of cells. The cells were stored in a liquid nitrogen tank at -7O⁰C after adding a culture medium for freezing, and cultivated by thawing just before using.

(2) Nitric oxide Secretion Test Sample and RAW264.7 (2x10⁵) cell were put into a 96-well plate, and then cultivated in a CO2 incubator maintaining the temperature at 37°C for 48 hours. Nitrite concentration of the culture medium was determined by a microplate assay as follows: After cultivating for 48 hours, 50 μl aliquots from the supernatant was taken, and the same volume of Griess reagent (1 % sulfanilamide/0.1% naphthylethylene diamine dihydrochloride in 2.5% HaPO₄) was then added thereto. The resultant was reacted at an ambient temperature for 10 minutes. Standard curve was obtained by measuring the absorbencies at 540 nm by ELISA reader (Molecular Device, USA) using sodium nitrite as a standard of nitrite. Using this standard curve, the content of Nitric oxide secreted from the cells due to the composition prepared in Examples 1 to 4 was determined.

(3) lnterleukin-1α Secretion In accordance with the same procedure as in measuring the reactive nitrogen species secretion, sample and RAW264.7 (2x10⁵) cell were put into a 96-well plate, and then were cultivated in a CO₂ incubator maintaining the temperature at 37⁰C for 48 hours. After taking the supernatant, lnterleukin-1α (IL-1α) secreted from a macrophage was determined with an enzyme-linked immunosorbent assay (ELISA) according to the procedure presented in Figure 2. Specifically, after a blocking reagent was added in order to prevent unspecific response of an antibody against the microtiter plate coated with anti-mlL-1α monoclonal antibody, cells were washed three times with a buffer solution for washing. 50 μl of biotinylated anti-mll_-1α was put into the cleaned

plate, and 50 μl of standard IL-1α or cultivated sample liquid were injected into wells, and the plate was then cultivated at 25⁰C for 2 hours. The cultivated plate was washed three times again with a buffer solution for washing, and 100 μl of streptavidin-conjugated horse reddish peroxidase was added thereto. The resultant was reacted at 25°C and then washed with a buffer solution for washing. After coloring reaction was performed at 25°C for 30 minutes by adding 100 μl of substrate (3,3',5,5'-tetramethyl benzidine)

thereto, the reaction was quenched by adding 100 μl of 1N sulfuric acid. Standard curve was obtained by measuring the absorbencies at 450 nm using ELISA reader (Molecular device, USA). Using this standard curve, IL-1α content secreted from the cells due to the composition prepared in Examples 1 to 4 was determined.

(4) Tumor Necrosis Factor Secretion

In order to check if a sample enhances ability to produce the tumor necrosis factor (TNF) of a macrophage, the same procedure as in determining the IL-1α secretion was performed, and TNF secretion ability was evaluated using ELISA. Specifically, 50 μl of standard TNF or the cultivated

sample liquid, together with 50 μl of biotinylated anti-mTNF, was respectively injected into the wells of the microtiter plate, and cultivated at 25°C for 2 hours. The cultivated plate was washed with a buffer solution for washing 5 times, and 100 μl of HRP-conjugated anti-mTNF was added thereto. The resultant was cultivated at 25°C for 30 minutes and then washed with a buffer solution for washing 5 times. 100 μl of the substrate (S.S'.S.δ'-tetramethyl benzidine) was added thereto. After carrying out coloring reaction at 25⁰C for 30 minutes, the reaction was quenched by adding 100 μl of 1N sulfuric acid. Standard curve was obtained by measuring absorbencies at 450 nm using ELISA reader. Using this standard curve, TNF content secreted from the cell due to the composition manufactured in Examples 1 to 4 was determined.

Table 5 below shows the immune activities of the tablet milk compositions prepared in Examples 1 to 4 which were determined according to the procedures described above.

Table 5

Notes) When the added concentration was 0, IL-1α was undetected, nitric oxide was undetected, and TNF was 32.42 pg/ml.

Claims

1. A tablet milk composition having immuno-modulating activity, comprising 50 to 70% by weight of skim milk powder, 3.0 to 7.0% by weight of Acanthopanax senticosus extract powder, 1.0 to 3.0% by weight of Radix Adenophorae extract powder, 1.0 to 3.0% by weight of Agaricus bisporus extract powder or Agaricus bisporus powder, and 1.0 to 3.0% by weight of Pleurotus ostreatus extract powder or Pleurotus ostreatus* powder to the total weight of the composition; and surface coating of hydroxypropylmethylcellulose.

2. The tablet milk composition according to claim 1 , further comprising 0-10.0% by weight of colostrum powder, 0.5-2.0% by weight of Ganoderma lucodum extract powder, 0.5-2.0% by weight of Phellinus linteus extract powder, 3.0-7.0% by weight of ginseng powder, 0.2-1.0% by weight of lactoferrin, 5.0-15.0% by weight of glutamine peptide, 1.0-5.0% by weight of lactose and 1.0-3.0% by weight of crystalline oligosaccharide.

3. A preparation method of the tablet milk composition according to claim 1 or 2, comprising:

(1) mixing Acanthopanax senticosus extract powder, Radix Adenophorae extract powder, Agaricus bisporus extract powder or Agaricus bisporus powder, and Pleurotus ostreatus* extract powder or Pleurotus ostreatus* powder, with or without at least one ingredients selected from the group consisting of colostrum powder, Ganoderma lucodum extract powder, Phellinus linteus extract powder, ginseng powder, lactoferrin, glutamine peptide, lactose, crystalline oligosaccharide and mixtures thereof, at 10 to 2O⁰C for 20 to 60 minutes with Hobert mixer;

(2) adding 50 to 70% by weight of skim milk powder based on the total weight of the composition to the mixture obtained from said step (1 ), followed by homogeneously blending;

(3) aging the resultant from said step (2) at 5 to 15°C for 2 to 5 hours; (4) preparing tablets from the aged mixture obtained from said step (3); and

(5) coating the tablets obtained from said step (4) with 3% hydroxypropylmethylcellulose solution.